C4 Therapeutics(CCCC) - 2024 Q3 - Quarterly Results

Exhibit 99.1 C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Cemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin's Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA Initial Monotherapy CFT1946 Phase 1 Data Demonstrated Well-Tolerated Safety Profile and Early Evidence of Antitumor Activity; Phase 1/2 Trial Continues to Progress with Multiple Data Re ...